NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc
(AIM: RENX), a developer of artificial intelligence-enabled
clinical diagnostics for kidney disease, announced today the
appointment of leading kidney investigator and clinician Dr.
Chirag Parikh to the Renalytix
board.
Dr. Parikh is the Director of the Division of Nephrology and the
Ronald Peterson Professor of Medicine at the Johns Hopkins School of Medicine. Dr. Parikh
received his medical degree from Seth G.S. Medical College and KEM
Hospital in Mumbai, India and
subsequently completed his internal medicine residency at the
Nassau University Medical Center and SUNY at Stony
Brook in New York, followed
by his fellowship in Nephrology and Hypertension and UNOS
Transplant Certification at the University of
Colorado. While completing his fellowship, he also earned a
doctorate in Clinical Investigation. Before joining Johns Hopkins, he was faculty at the Yale School of Medicine for over a decade and also
directed the Program of Applied Translational Research. He was also
promoted to Professor of Medicine and Investigative Medicine at
Yale, and Professor of Medicine at the
Clinical Epidemiology Research Center in the VA Connecticut Health
Care System.
Dr. Parikh has several active NIH grants and has published over
250 original articles, which have been cited over 35,000 times in
literature. Dr. Parikh's research focuses on the translation and
validation of novel biomarkers for the diagnosis and prognosis of
acute kidney injury. Progress in kidney diseases has been hamstrung
by significant heterogeneity within the current disease
definitions, which are largely based on serum creatinine. Dr.
Parikh's research has addressed this critical challenge by
developing biomarkers of renal tubular injury, repair, and
inflammation to dissect this heterogeneity. He has assembled
multicenter longitudinal prospective cohorts for translational
research studies across several clinical settings of acute kidney
injury and chronic kidney disease for the efficient translation of
novel biomarkers.
Dr. Parikh's studies have refined the clinical definition in
perioperative acute kidney injury and hepatorenal syndrome,
developed strategies to reduce kidney discard in deceased donor
transplantation, and advanced regulatory approvals of kidney injury
biomarkers. He has also developed biomarkers to identify rapid
progressors of early diabetic kidney disease before derangements in
serum creatinine. Dr. Parikh's research goal is to translate our
understanding of pathophysiological mechanisms into clinical
practice and improve the outcomes in patients with kidney
disease.
Dr. Parikh has also been the recipient of numerous honors,
including the 2017 Young Investigator Award from the American
Society of Nephrology, in recognition of his ability to translate
findings in the laboratory to the advancement of clinical
outcomes.
"We are honored to have one of the leading voices in kidney
disease clinical practice and research join our board," said
James McCullough, CEO of
RenalytixAI. "Chirag will help ensure we maintain the highest
standards of data driven development for the KidneyIntelX
program."
About Kidney Disease
Kidney disease is now
recognized as a public health epidemic affecting over 850 million
people globally. In the United
States alone, over 40 million people are classified as
having chronic kidney disease, with nearly 50 percent of
individuals with advanced (Stage IV) disease unaware of the
severity of their reduced kidney function. As a result, many
patients progress to kidney failure in an unplanned manner, ending
up having dialysis in the emergency room without ever seeing a
clinical specialist, such as a nephrologist. Every day 13 patients
die in the United States while
waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of
artificial intelligence-enabled clinical diagnostic solutions for
kidney disease, one of the most common and costly chronic medical
conditions globally. The Company's solutions are being designed to
make significant improvements in kidney disease diagnosis and
prognosis, clinical care, patient stratification for drug clinical
trials, and drug target discovery. For more information, visit
renalytixai.com.
View original
content:http://www.prnewswire.com/news-releases/johns-hopkins-director-of-nephrology-chirag-parikh-joins-renalytixai-board-300937756.html
SOURCE RenalytixAI